Good afternoon :)
Cohance Lifesciences Ltd

Cohance Lifesciences Ltd

COHANCE Share Price

NSE
486.951.18% (+5.70)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹18,411 cr, stock is ranked 377

Stock is 3.71x as volatile as Nifty

COHANCE Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹18,411 cr, stock is ranked 377

Stock is 3.71x as volatile as Nifty

COHANCE Performance & Key Metrics

COHANCE Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
65.7310.00
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
41.106.150.54%

COHANCE Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
67%
Analysts have suggested that investors can buy this stock

from 9 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

COHANCE Company Profile

Cohance Lifesciences Limited is a technology-driven CDMO in India, offering custom synthesis, process R&D, and manufacturing services for pharmaceuticals and specialty chemicals.

Investor Presentation

View older View older 

Feb 12, 2026

PDF
View Older Presentations

COHANCE Similar Stocks (Peers)

Compare with peers Compare with peers 

COHANCE Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
40.62
40.62
1Y Return
1.71%
1.71%
Buy Reco %
96.67
96.67
PE Ratio
77.18
77.18
1Y Return
33.28%
33.28%
Buy Reco %
77.78
77.78
PE Ratio
34.04
34.04
1Y Return
19.22%
19.22%
Buy Reco %
73.53
73.53
PE Ratio
20.90
20.90
1Y Return
9.73%
9.73%
Buy Reco %
50.00
50.00
PE Ratio
19.30
19.30
1Y Return
12.98%
12.98%
Buy Reco %
48.39
48.39
Compare with Peers

COHANCE Sentiment Analysis

COHANCE Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

COHANCE Stock Summary · February 2026

Cohance Lifesciences is navigating a challenging transition year, particularly in its Pharma CDMO segment, where destocking and delays linked to a significant molecule nearing patent expiry have impacted program timelines. Despite these hurdles, the company is witnessing increased engagement from global innovators and has successfully converted a late-stage commercial RFP into a confirmed program, bolstering its robust late-stage pipeline of nine Phase 3 programs. The Specialty Chemicals segment has shown resilience with a 32% year-on-year revenue growth, while the API Plus segment faces regulatory challenges that have led to an 8% revenue decline. Management remains cautiously optimistic about recovery in FY '27, focusing on diversification and strategic partnerships to enhance market positioning and mitigate margin pressures. Overall, while current financial performance reflects volatility, the long-term outlook is supported by a strong pipeline and proactive business development efforts.

COHANCE Stock Growth Drivers
COHANCE Stock Growth Drivers
9
  • Strong Late-Stage Pipeline

    The company supports a robust late-stage pipeline with nine Phase 3 programs, providing medium-term visibility

  • Increased Customer Engagement

    There has been a notable increase in customer engagement, particularly with global innovators and large

COHANCE Stock Challenges
COHANCE Stock Challenges
4
  • Revenue Decline and Financial Performance Issues

    The company has experienced a significant revenue decline, with a reported 6.7% decrease in revenue

  • Operational Challenges and Delays

    The company is facing operational challenges, including customer-led delays in product reloads and off-take due

COHANCE Forecast

COHANCE Forecasts

Price

Revenue

Earnings

COHANCE

COHANCE

Income

Balance Sheet

Cash Flow

COHANCE Income Statement

COHANCE Income Statement

Loading...

Quartersep 2023dec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025
Total Revenue250.90234.16269.98507.49619.96697.79852.47563.48571.17550.71
Operating & Other expensessubtract133.09153.74179.59362.98398.40438.86626.98445.40434.62454.06
Depreciation/Amortizationsubtract11.8912.7917.2531.2837.7943.5654.1745.1444.0246.94
Interest & Other Itemssubtract0.502.162.3010.209.6110.8010.4510.188.769.11
Taxes & Other Itemssubtract25.8418.7217.4827.6635.6951.5040.4413.889.693.88
EPS3.131.842.101.983.634.023.161.281.940.96

COHANCE Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual Report Pending

Investor Presentation

Feb 12PDF
Nov 12PDF
Aug 13PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 28PDF
Feb 12PDF
Nov 12PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

Aug 8PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 9PDF
May 9PDF
Feb 8PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
 

COHANCE Stock Peers

COHANCE Past Performance & Peer Comparison

COHANCE Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Cohance Lifesciences Ltd68.7310.00
Sun Pharmaceutical Industries Ltd40.626.120.86%
Torrent Pharmaceuticals Ltd77.1819.430.73%
Lupin Ltd34.046.460.49%

COHANCE Stock Price Comparison

Compare COHANCE with any stock or ETF
Compare COHANCE with any stock or ETF
COHANCE
Loading...

COHANCE Holdings

COHANCE Shareholdings

COHANCE Promoter Holdings Trend

COHANCE Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

COHANCE Institutional Holdings Trend

COHANCE Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

COHANCE Shareholding Pattern

COHANCE Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding57.49%18.57%3.22%5.59%15.13%

Jun 2025

Sep 2025

Dec 2025

Mar 2026

COHANCE Shareholding History

COHANCE Shareholding History

MarMayJunSepDec '25Mar11.05%7.38%7.23%6.51%6.02%5.59%

Mutual Funds Invested in COHANCE

Mutual Funds Invested in COHANCE

No mutual funds holding trends are available

Top 5 Mutual Funds holding Cohance Lifesciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.0855%3.18%0.17%11/44 (-2)
0.6784%0.13%-0.08%273/338 (-8)
0.6549%0.13%-0.09%65/69 (-11)

Compare 3-month MF holding change on Screener

COHANCE Insider Trades & Bulk Stock Deals

COHANCE Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing COHANCE stock

smallcases containing COHANCE stock

Looks like this stock is not in any smallcase yet.

COHANCE Events

COHANCE Events

COHANCE Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

COHANCE Dividend Trend

No dividend trend available

COHANCE Upcoming Dividends

COHANCE Upcoming Dividends

No upcoming dividends are available

COHANCE Past Dividends

COHANCE Past Dividends

Cash Dividend

Ex DateEx DateSep 9, 2022

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 9, 2022

Cash Dividend

Ex DateEx DateSep 9, 2022

Special
Special | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Sep 9, 2022

Cash Dividend

Ex DateEx DateMay 13, 2022

Interim 2
Interim 2 | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

May 13, 2022

Cash Dividend

Ex DateEx DateMay 13, 2022

Special
Special | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

May 13, 2022

Cash Dividend

Ex DateEx DateFeb 15, 2022

Special
Special | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Feb 15, 2022

COHANCE Stock News & Opinions

COHANCE Stock News & Opinions

Corporate
Cohance Lifesciences to discuss results

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 May 2026.

2 hours agoCapital Market - Live
Spotlight
Cohance Lifesciences Ltd leads gainers in 'A' group

AGI Greenpac Ltd, Black Box Ltd, Electronics Mart India Ltd and Epack Durable Ltd are among the other gainers in the BSE's 'A' group today, 28 April 2026.Cohance Lifesciences Ltd surged 15.30% to Rs 498.9 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 20.16 lakh shares were traded on the counter so far as against the average daily volumes of 5.45 lakh shares in the past one month. AGI Greenpac Ltd spiked 12.13% to Rs 633.05. The stock was the second biggest gainer in 'A' group. On the BSE, 2.77 lakh shares were traded on the counter so far as against the average daily volumes of 15484 shares in the past one month. Black Box Ltd soared 10.24% to Rs 638.75. The stock was the third biggest gainer in 'A' group. On the BSE, 1.94 lakh shares were traded on the counter so far as against the average daily volumes of 20649 shares in the past one month. Electronics Mart India Ltd added 10.00% to Rs 121.5. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.01 lakh shares were traded on the counter so far as against the average daily volumes of 33506 shares in the past one month. Epack Durable Ltd exploded 8.58% to Rs 292.85. The stock was the fifth biggest gainer in 'A' group. On the BSE, 15.37 lakh shares were traded on the counter so far as against the average daily volumes of 68544 shares in the past one month.

1 week agoCapital Market - Live
Spotlight
Cohance Lifesciences Ltd leads gainers in 'A' group

India Cements Ltd, Tanla Platforms Ltd, Blue Jet Healthcare Ltd and Epack Durable Ltd are among the other gainers in the BSE's 'A' group today, 27 April 2026.Cohance Lifesciences Ltd soared 19.99% to Rs 432.7 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 15.19 lakh shares were traded on the counter so far as against the average daily volumes of 4.86 lakh shares in the past one month. India Cements Ltd surged 12.10% to Rs 457.05. The stock was the second biggest gainer in 'A' group. On the BSE, 6.92 lakh shares were traded on the counter so far as against the average daily volumes of 10613 shares in the past one month. Tanla Platforms Ltd spiked 11.33% to Rs 541.5. The stock was the third biggest gainer in 'A' group. On the BSE, 4.43 lakh shares were traded on the counter so far as against the average daily volumes of 38325 shares in the past one month. Blue Jet Healthcare Ltd exploded 9.99% to Rs 443.75. The stock was the fourth biggest gainer in 'A' group. On the BSE, 1.05 lakh shares were traded on the counter so far as against the average daily volumes of 27090 shares in the past one month. Epack Durable Ltd rose 8.63% to Rs 253.1. The stock was the fifth biggest gainer in 'A' group. On the BSE, 52724 shares were traded on the counter so far as against the average daily volumes of 37732 shares in the past one month.

1 week agoCapital Market - Live
Spotlight
Cohance Lifesciences soars after appointing Umang Vohra as chairman & CEO.

Vohra will succeed Vivek Sharma, who is stepping down as executive chairman for personal reasons. Sharma will continue with Cohance as an advisor for the next nine months to ensure a smooth transition. Vohra is one of the most accomplished leaders in the pharmaceutical industry. Over a career spanning more than three decades, he has led large, complex, global businesses through periods of strategic transformation while maintaining an unwavering focus on customers, quality and operational excellence. Most recently, as CEO and managing director of Cipla, Vohra led the company's transformation over the last decade to build a diversified global pharmaceutical enterprise. Having worked in and transformed two very large and respected Pharma companies in India, Vohra brings an owner-mindset and vast experience in business to the Cohance platform. The company said the appointment reflects a deliberate, strategic decision taken by the board, to bring in a leader whose profile is specifically suited to the demands of Cohance's transformation and its next phase of growth. Commenting on appointment, Umang Vohra said, 'I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance's technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike. Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. It is a technology-driven, integrated CDMO platform offering development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides and advanced chemistries for global pharmaceutical and life sciences customers. The company's consolidated net profit dropped 76% to Rs 36.72 crore on 19.5% decline in revenue from operations to Rs 544.55 crore in Q3 FY26 over Q3 FY25.

1 week agoCapital Market - Live
Corporate
Board of Cohance Lifesciences approves change in chairman

The board of Cohance Lifesciences at its meeting held on 27 April 2026 has approved the following: Noted the resignation of Vivek Sharma (DIN 08559495), as Executive Chairman and director of the Company with effect from 30 April 2026. Approved the appointment of Umang Vohra as Additional Director, designated as Chairman, and Group Chief Executive Officer with effect from 01 May 2026 and 20 May 2026 respectively.

1 week agoCapital Market - Live
Earnings
Cohance Lifesciences consolidated net profit declines 76.01% in the December 2025 quarter

Net profit of Cohance Lifesciences declined 76.01% to Rs 36.72 crore in the quarter ended December 2025 as against Rs 153.07 crore during the previous quarter ended December 2024. Sales declined 19.47% to Rs 544.55 crore in the quarter ended December 2025 as against Rs 676.23 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales544.55676.23 -19 OPM %17.5135.10 - PBDT92.40248.13 -63 PBT45.46204.57 -78 NP36.72153.07 -76 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Cohance Lifesciences receives warning letter from USFDA for its Hyderabad unit

 Cohance Lifesciences announced that the US FDA conducted an inspection at the Company's Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from 04 August 2025 to 12 August 2025. Following the inspection, a Form FDA-483 containing six observations was issued by the US FDA. Based on these observations, the USFDA classified the facility as 'Official Action Indicated (OAI)' and subsequently issued a Warning Letter for the said facility. The Company is required to respond to the Warning Letter within the stipulated timelines prescribed by the US FDA and continues to engage with the regulator thereafter. The US revenues from this facility contributed less than 2% of consolidated revenues in FY25, with related EBITDA contribution below 1%. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Cohance Lifesciences receives warning letter for its Nacharam formulation facility

Pursuant to the USFDA inspection, Cohance Lifesciences has received a warning letter for the company's Nacharam formulation facility. The Company had earlier informed the Stock Exchanges that the facility was classified as Official Action Indicated (OAI), and the said Warning Letter is in continuation of the same. The inspection was conducted by the USFDA from 04 August 2025 to 12 August 2025. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Cohance Lifesciences to convene board meeting

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Cohance Lifesciences Ltd leads losers in 'A' group

Endurance Technologies Ltd, Time Technoplast Ltd, Jyoti CNC Automation Ltd and Lemon Tree Hotels Ltd are among the other losers in the BSE's 'A' group today, 13 November 2025.Cohance Lifesciences Ltd lost 8.38% to Rs 631.75 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.69 lakh shares were traded on the counter so far as against the average daily volumes of 67428 shares in the past one month.Endurance Technologies Ltd tumbled 7.67% to Rs 2692.6. The stock was the second biggest loser in 'A' group.On the BSE, 15663 shares were traded on the counter so far as against the average daily volumes of 7578 shares in the past one month.Time Technoplast Ltd crashed 6.14% to Rs 201. The stock was the third biggest loser in 'A' group.On the BSE, 2.33 lakh shares were traded on the counter so far as against the average daily volumes of 59774 shares in the past one month.Jyoti CNC Automation Ltd fell 5.61% to Rs 933.5. The stock was the fourth biggest loser in 'A' group.On the BSE, 45463 shares were traded on the counter so far as against the average daily volumes of 78342 shares in the past one month.Lemon Tree Hotels Ltd shed 4.85% to Rs 155.1. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.9 lakh shares were traded on the counter so far as against the average daily volumes of 1.34 lakh shares in the past one month.Powered by Capital Market - Live

5 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Cohance Lifesciences Ltd (COHANCE) today?

    The share price of COHANCE as on 7th May 2026 is ₹486.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Cohance Lifesciences Ltd (COHANCE) share?

    The past returns of Cohance Lifesciences Ltd (COHANCE) share are
    • Past 1 week: -0.46%
    • Past 1 month: 57.50%
    • Past 3 months: 41.77%
    • Past 6 months: -33.52%
    • Past 1 year: -57.02%
    • Past 3 years: 1.33%
    • Past 5 years: -11.23%

  3. What are the peers or stocks similar to Cohance Lifesciences Ltd (COHANCE)?
  4. What is the market cap of Cohance Lifesciences Ltd (COHANCE) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cohance Lifesciences Ltd (COHANCE) is ₹18411.04 Cr as of 7th May 2026.

  5. What is the 52 week high and low of Cohance Lifesciences Ltd (COHANCE) share?

    The 52-week high of Cohance Lifesciences Ltd (COHANCE) is ₹1158.30 and the 52-week low is ₹266.70.

  6. What is the PE and PB ratio of Cohance Lifesciences Ltd (COHANCE) stock?

    The P/E (price-to-earnings) ratio of Cohance Lifesciences Ltd (COHANCE) is 68.73. The P/B (price-to-book) ratio is 10.00.

  7. Which sector does Cohance Lifesciences Ltd (COHANCE) belong to?

    Cohance Lifesciences Ltd (COHANCE) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Cohance Lifesciences Ltd (COHANCE) shares?

    You can directly buy Cohance Lifesciences Ltd (COHANCE) shares on Tickertape. Simply sign up, connect your demat account and place your order.